Welcome to our dedicated page for Travere Therapeutics news (Ticker: TVTX), a resource for investors and traders seeking the latest updates and insights on Travere Therapeutics stock.
Travere Therapeutics Inc (TVTX) is a biopharmaceutical innovator developing therapies for rare kidney, liver, and metabolic diseases. This page provides a comprehensive repository of official company announcements, clinical trial updates, and regulatory developments.
Investors and researchers will find curated press releases detailing milestones for pipeline candidates like FILSPARI and sparsentan, along with financial disclosures and partnership announcements. Content is organized to highlight material events including FDA communications, trial phase completions, and strategic collaborations.
All updates are sourced directly from Travere Therapeutics to ensure accuracy. Bookmark this page for efficient tracking of the company’s progress in advancing treatments for IgA nephropathy, FSGS, and other rare conditions.
On February 28, 2022, Travere Therapeutics (NASDAQ: TVTX) joined global organizations like NORD and EURORDIS in acknowledging Rare Disease Day. This day highlights the struggles of approximately 400 million people worldwide affected by rare diseases, which often lack approved treatments. CEO Eric Dube emphasized the importance of listening to the rare community for innovation and support. Travere also launched the Rare Life campaign to share the experiences of those with rare kidney, metabolic, and liver disorders. A workforce panel discussed IgA nephropathy, a serious condition affecting many young adults.
Travere Therapeutics (NASDAQ: TVTX) reported a 6% increase in net product sales to $211 million for 2021. The company is set to submit NDAs for accelerated approvals of sparsentan in IgA nephropathy and FSGS in 2022. Positive interim results from the Phase 3 PROTECT Study showed significant proteinuria reduction. R&D expenses rose to $210.3 million, reflecting ongoing studies. The net loss for 2021 was $180.1 million, with cash reserves of $552.9 million as of December 31, 2021. Management expresses optimism for continued growth and regulatory submissions.
Travere Therapeutics (NASDAQ: TVTX) announced on February 10, 2022, that its Compensation Committee granted inducement equity grants totaling 70,600 shares to seven new employees. This includes stock options for 25,000 shares and restricted stock units (RSUs) for 45,600 shares, pursuant to its 2018 Equity Incentive Plan. The stock options have an exercise price of $27.42 and vest over four years, with the RSUs also vesting over the same period. These grants are intended to incentivize new hires and are compliant with Nasdaq rules.
Travere Therapeutics, Inc. (NASDAQ: TVTX) announced it will disclose its fourth quarter and full year 2021 financial results on February 24, 2022, after U.S. markets close. A conference call to discuss these results and provide a business update will take place at 4:30 p.m. ET the same day. Interested parties can access a live webcast through Travere’s website. A replay of the call will be available from 7:30 p.m. ET on February 24 until March 3, 2022. For more information, visit Travere.com.
SAN DIEGO, Feb. 09, 2022 – Travere Therapeutics (NASDAQ: TVTX) announced that CEO Eric Dube will present at the virtual 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 2:20 p.m. ET. A live webcast will be available on their investor relations website, and an archived replay will be accessible for 30 days. Travere Therapeutics is dedicated to supporting patients with rare diseases by developing life-changing therapies and collaborating with the rare disease community.
Travere Therapeutics (NASDAQ: TVTX) announced on January 10, 2022, that its Compensation Committee granted inducement equity to five new employees. This includes stock options for 33,000 shares and RSUs for 9,000 shares, all under the terms of the 2018 Equity Incentive Plan but granted as inducements to employment. The options have an exercise price of $28.04, vesting over four years, while the RSUs also vest over the same period. These grants comply with Nasdaq Listing Rule 5635(c)(4), aimed at attracting and retaining talent in the biopharmaceutical sector.
Travere Therapeutics (NASDAQ: TVTX) announced its expectations for Q4 2021 net product sales of approximately $55 million and total fiscal year 2021 revenues of $227 million. The company is advancing its pipeline, including the investigational drug sparsentan for rare kidney diseases IgA nephropathy and FSGS, with plans for New Drug Applications (NDA) submissions in 2022. Additionally, pegtibatinase is indicated as a potential first treatment for classical homocystinuria. Full financial results are expected to be released in late February.
Travere Therapeutics (NASDAQ: TVTX) appoints Jula Inrig, M.D., as Chief Medical Officer, effective immediately. Dr. Inrig, with over 15 years in drug development, clinical trials, and regulatory engagement, joins the company as it gears up for accelerated approval submissions of sparsentan for IgA nephropathy and focal segmental glomerulosclerosis in 2022. Her extensive background includes executing over 45 clinical trials at IQVIA, leading to FDA and EMA approvals. The company also approved inducement awards of 80,000 stock options and 20,000 restricted stock units as part of her employment package.
Travere Therapeutics (NASDAQ: TVTX) announced positive topline results from its ongoing Phase 1/2 COMPOSE Study of pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). The highest dose cohort (1.5mg/kg BIW) showed a clinically meaningful 55.1% mean reduction in total homocysteine after 12 weeks, maintaining levels below 100 μmol. The treatment was well-tolerated with no discontinuations due to adverse events. The company plans to engage regulators for a pivotal development program to support potential approvals.
Travere Therapeutics (NASDAQ: TVTX) announced the granting of inducement equity grants totaling 71,350 shares to five new employees on December 10, 2021. This includes stock options for 58,500 shares and restricted stock units (RSUs) for 12,850 shares, granted outside the 2018 Equity Incentive Plan. The stock options have an exercise price of $26.76, vesting over four years, while RSUs also vest over four years, contingent on continued employment. These grants are part of the company’s strategy to attract talent within the biopharmaceutical sector.
FAQ
What is the current stock price of Travere Therapeutics (TVTX)?
What is the market cap of Travere Therapeutics (TVTX)?
